- Home
- UP vs SNDX Comparison
UP vs SNDX Comparison
Compare UP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- SNDX
- Stock Information
- Founded
- UP 2013
- SNDX 2005
- Country
- UP United States
- SNDX United States
- Employees
- UP N/A
- SNDX N/A
- Industry
- UP Aerospace
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- SNDX Health Care
- Exchange
- UP Nasdaq
- SNDX Nasdaq
- Market Cap
- UP 1.2B
- SNDX 1.1B
- IPO Year
- UP N/A
- SNDX 2016
- Fundamental
- Price
- UP $1.62
- SNDX $12.80
- Analyst Decision
- UP
- SNDX Strong Buy
- Analyst Count
- UP 0
- SNDX 10
- Target Price
- UP N/A
- SNDX $36.20
- AVG Volume (30 Days)
- UP 1.3M
- SNDX 2.7M
- Earning Date
- UP 03-06-2025
- SNDX 02-25-2025
- Dividend Yield
- UP N/A
- SNDX N/A
- EPS Growth
- UP N/A
- SNDX N/A
- EPS
- UP N/A
- SNDX N/A
- Revenue
- UP $833,669,000.00
- SNDX $16,000,000.00
- Revenue This Year
- UP $38.03
- SNDX N/A
- Revenue Next Year
- UP $25.66
- SNDX N/A
- P/E Ratio
- UP N/A
- SNDX N/A
- Revenue Growth
- UP N/A
- SNDX N/A
- 52 Week Low
- UP $1.52
- SNDX $12.40
- 52 Week High
- UP $4.59
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- UP 37.97
- SNDX 36.65
- Support Level
- UP $1.52
- SNDX $12.40
- Resistance Level
- UP $1.87
- SNDX $14.65
- Average True Range (ATR)
- UP 0.12
- SNDX 0.61
- MACD
- UP -0.00
- SNDX 0.14
- Stochastic Oscillator
- UP 27.14
- SNDX 17.78
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.